Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 3/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13644972 | 0.92 | MAPT (0.47) | MAPTALDH1A1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL13644978 | 0.88 | MAPT (0.44) | MAPTALDH1A1HTTHTR3EHTR3B | |
| SCHEMBL13603840 | 0.88 | MAPT (0.44) | MAPTALDH1A1RAB9APTGIRRXRA | |
| SCHEMBL340808 | 0.86 | CRHBP (0.47) | ALDH1A1HTTRAB9AL3MBTL1KMT2A | |
| SCHEMBL13644983 | 0.85 | MAPT (0.42) | MAPTALDH1A1SMN1; SMN2PTGIRPTGDR | |
| SCHEMBL13645007 | 0.85 | MAPT (0.50) | MAPTALDH1A1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL13603786 | 0.84 | FABP4 (0.46) | MAPTALDH1A1HTTRAB9AMEN1 | |
| SCHEMBL9779983 | 0.82 | HTR3E (0.44) | MAPTALDH1A1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL20322974 | 0.82 | HTR3E (0.47) | MAPTALDH1A1HTR3EHTR3BHTR3A | |
| SCHEMBL13644989 | 0.81 | EPHX2 (0.60) | RAB9AL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975707-B1 | Curable composition and planographic printing plate precursor | FUJIFILM CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-1801651-B1 | Polymerizable composition and planographic printing plate precursor using the same | FUJIFILM CORP (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-1431032-B1 | Polymerizable composition and lithographic printing plate precursor | FUJIFILM CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| EP-2039509-B1 | Curable composition, image forming material, and planographic printing plate precursor | FUJIFILM CORP (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-0730201-B1 | Sensitized photopolymerizable compositions and use thereof in lithographic printing plates | KODAK POLYCHROME GRAPHICS LLC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1079972-A1 | IR-SENSITIVE COMPOSITION AND USE THEREOF FOR THE PREPARATION OF PRINTING PLATE PRECURSORS | Kodak Polychrome Graphics Company Ltd. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000048836-A1 | IR-SENSITIVE COMPOSITION AND USE THEREOF FOR THE PREPARATION OF PRINTING PLATE PRECURSORS | KODAK POLYCHROME GRAPHICS COMPANY, LTD. (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5942372-A | COMPRISED A SPECTRAL SENSITIZER THAT SENSITIZES IN THE ULTRAVIOLET OR VISIBLE REGIONS OF THE SPECTRUM AND AN N-ARYL POLYCARBOXYLIC ACID CO-INITIATOR; VERY HIGH PHOTOSPEED AND VERY GOOD SHELF-LIFE IN COMPUTER-TO-PLATE SYSTEMS | KODAK POLYCHROME GRAPHICS, LLC (US) | 1999-08-24 | — | — | US | disclosed |
| US-5914215-A | ELEMENT COMPRISING SUPPORT HAVING PHOTOIMAGEABLE, RADIATION SENSITIVE LAYER COMPRISING UNSATURATED COMPOUND, PHOTOINITIATOR SYSTEM COMPRISING SENSITIZER SENSITIZING IN ULTRAVIOLET OR VISIBLE REGION OF SPECTRUM, CO-INITIATOR | KODAK POLYCHROME GRAPHIC, LLC (US) | 1999-06-22 | — | — | US | disclosed |
| US-5888700-A | NONFOGGING, SHELF LIFE | KODAK POLYCHROME GRPAHICS, LLC (US) | 1999-03-30 | — | — | US | disclosed |
| US-5821030-A | DIRECT DIGITAL EXPOSURE; HIGH WRITING SPEED; ADHESION; ANTIFOGGING AGENTS; SHELF LIFE; USING A POLYCARBOXYLIC ACID IN THE PHOTOPOLYMERIZATION INITIATOR SYSTEM AND A BASIC COMPOUND IN THE OXYGEN BARRIER LAYER | KODAK POLYCHROME GRAPHICS (US) | 1998-10-13 | — | — | US | disclosed |
| EP-0795790-A2 | Peel-developable lithographic printing plate | EASTMAN KODAK COMPANY (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5629354-A | Photopolymerization initiator system comprising a spectral sensitizer and a polycarboxylic acid co-initiator | EASTMAN KODAK COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0730201-A1 | Sensitized photopolymerizable compositions and use thereof in lithographic printing plates | EASTMAN KODAK COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | MAPT 230/4885ALDH1A1 180/4885HTT 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.